A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
Completed · Phase 1
Conditions studied: Malignant Solid Tumor, Solid Tumor, Metastatic Tumor
In brief
The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.
Key facts
- Study ID
- NCT01648764
- Run by
- Eli Lilly and Company
- People needed
- 73
- Starts
- 2008-09-01
- Expected to finish
- 2012-11-01
- Last updated by the study team
- 2019-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of advanced and/or metastatic cancer (including lymphoma) for which no treatment of higher priority exists
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Estimated life expectancy of more than 12 weeks
- Have discontinued all previous therapies for cancer for at least 30 days (6 weeks for mitomycin-C or nitrosoureas) and recovered from acute effects of therapy
- Have discontinued radiotherapy more than one week before enrolling in the study and have recovered from the acute effects of therapy
- Have adequate organ function
- Follow your doctor's directions and live close enough to the study site so you can continue to go to the clinic for follow-up
- Are willing and able to swallow capsules and follow study procedures
- Have given written informed consent prior to any study-specific procedures
- Males and females with reproductive potential should use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug
- Females with child-bearing potential must have had a negative urine or serum pregnancy test 7 days prior to the first dose of study drug
You may not qualify if…
- Have gastrointestinal diseases or prior surgery that may interfere with the absorption of medication taken by mouth
- Females who are pregnant or lactating
- Symptomatic central nervous system malignancy or metastasis
- Known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb)
- Liver cirrhosis or chronic hepatitis
- Acute or chronic leukemia
- Are currently receiving treatment with valproic acid (VPA) and its derivatives, or if you have a history of intolerance to VPA
- Known hypersensitivity to gemcitabine
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Philadelphia, Pennsylvania, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Clichy, France
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Berlin, Germany
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Nuremberg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.